Serving as an interoperability platform, IntelliBridge Enterprise connects medical devices and hospital information systems to provide authorised healthcare professionals with a consolidated view of patient data. By allowing information to move smoothly between home care, clinics, ambulatory services and hospitals, the platform is intended to support faster clinical decision-making, minimise duplication of records, streamline care transitions and enhance coordination throughout a patient’s treatment journey. The project will also represent the first global deployment of Philips’ IntelliBridge Enterprise 3.0 Enterprise Cloud platform, making BIHS the first healthcare network worldwide to implement the latest cloud-based version of the technology.

Commenting on the collaboration, Bharath Sesha, Managing Director, Philips Indian Subcontinent, said, “Through our IntelliBridge Enterprise platform, we are enabling an integrated flow of patient information across the BIHS network, supporting better clinical decisions and improving efficiency.”

Nirav Bajaj, CEO and Managing Director, Bajaj Integrated Health System, said, “As we build out our network, the focus is on ensuring that care is integrated from the start, so that whether a patient enters through a clinic, a hospital or at home, the experience remains connected, coordinated and centred around their needs. Our collaboration with Philips brings in the digital backbone needed to enable seamless data flow across care settings, which is critical to delivering this integrated model.”

Alongside the digital platform, Philips will provide selected medical technologies across the BIHS network. These include the MR BlueSeal helium-free MRI system with Dual AI SmartSpeed and In-Bore Experience, technologies intended to enhance imaging performance, improve patient comfort and support operational sustainability. Through this initiative, Philips and BIHS are also seeking to strengthen healthcare infrastructure while advancing integrated care delivery across the country.

Under the proposal, which is scheduled for completion on Sept. 13, 2026, CMS would extend coverage to asymptomatic procedures while removing the coverage with evidence (CED) requirement currently applied to symptomatic TAVR procedures. The proposal also eliminates hospital volume requirements and removes specific operator criteria for newly established TAVR programs. The changes represent a significant update to the reimbursement landscape and are expected to simplify access to treatment for both providers and patients. The TAVR Coverage proposal maintains a CED requirement for asymptomatic procedures, a measure that BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber said was largely anticipated. They also noted that the volume thresholds required for TAVR programs remain attainable and should not create meaningful operational burdens.

According to the analysts, the proposed revisions are favorable not only for Edwards but also for other companies active in the space, including Medtronic and Abbott. They added that the broader TAVR market could benefit as well, potentially extending to Boston Scientific, which recently indicated plans to re-enter the market through an investment in MiRus. Discussing the impact of the proposal, the analysts said: “These are all positive changes that we expect will remove barriers and can eventually lead to higher TAVR procedure volumes.” They further stated: “We think this proposal is a good thing for TAVR volumes and if finalized, will serve as a tailwind for TAVR market leader [Edwards].” If adopted, the TAVR Coverage changes could help support greater procedure volumes across the industry.

The new offering builds on Helix, a product DeepIntent introduced in March that opened the data infrastructure supporting its own solutions to agencies such as Deerfield, Eversana, Klick Health and Trinity. Through Helix AI, marketers can interact with a database covering 4 million healthcare providers and 250 million patient lives. The technology is intended to streamline activities including audience sizing, prescriber overlap analysis and campaign performance measurement by reducing reliance on traditional database workflows.

Industry users say the technology can significantly reduce the time required for complex analysis. “Helix AI provides a strategic edge by putting advanced, purpose-built data capabilities directly into the hands of our strategists,” Liz Mansell, senior vice president, media strategy at Fingerpaint Marketing, said in a statement. “Analysis that once took days, and often wasn’t feasible at this depth, now takes minutes.” Agencies are also able to tailor the platform with their own first-party analytics, media assets and data sources. Supporters of the underlying Helix platform have highlighted efficiency gains, with Paul Cross, vice president, data strategy and reporting at Deerfield, stating in a DeepIntent video that workflows became 50% faster. Cross also said the platform transformed data management by bringing together information that had previously been spread across multiple systems.

The launch follows a period of significant activity for DeepIntent. Earlier this year, the company secured $637 million from Vitruvian Partners. Founded in 2016, DeepIntent was acquired by Propel Media in 2017 and later became the target of a buyout proposal from IQVIA in 2022, although that transaction was not completed after facing opposition from the Federal Trade Commission. Meanwhile, IQVIA has continued expanding its own AI portfolio, unveiling technology this week aimed at helping pharmaceutical marketers identify nurse practitioners and physician assistants who write prescriptions.

The Thunderbolt platform broadens Penumbra’s existing CAVT portfolio and is engineered to detect, fatigue and completely ingest clot during procedures. According to the company, the technology represents an advancement in acute ischemic stroke care and is powered by its Engine platform. With the European authorization, Penumbra said the device becomes the first and only CAVT technology available for stroke treatment in both the U.S. and Europe. The Thunderbolt Thrombectomy system will be supplied pre-packaged with one of the company’s catheter options, including Red 62, Red 68, Red 72, Silver Label or Red 72 Silver Label with SENDit technology.

The Alameda, California-based company described the approval as a significant milestone for its neurovascular business. Penumbra noted that the technology builds on two decades of research and development focused on clot-treatment solutions. The company also stated that it remains the only provider offering CAVT technology across both vascular and neurovascular care applications.

Commenting on the approval, Shruthi Narayan, president of Penumbra, said: “Thunderbolt is a culmination of two decades of research and innovation at Penumbra. By introducing CAVT to the neurovascular field in Europe, we are ushering in a new era of stroke management that will have a significant impact on patient care. We are the only company to offer CAVT technology across both vascular and neurovascular care as we are committed to transforming how life-threatening clots are treated from head-to-toe worldwide.”

Joan Kristensen, head of EMEA for Penumbra, added: “Thunderbolt has the potential to shorten procedure times improving patient safety, delivering better outcomes and streamlining care for the physicians who treat them. Bringing this technology to Europe is a significant milestone and a reflection of Penumbra’s ongoing commitment to putting the most advanced stroke care tools in the hands of physicians across the region.”

The agreement underscores a shared commitment between the two organizations to address evolving healthcare challenges through technology-driven innovation. By combining their respective expertise and resources, Kaopiz Holdings and QuantumTX aim to create AI healthcare solutions that enhance disease prevention and patient outcomes. The collaboration encompasses the integration of IoT engineering capabilities with advanced analytics to build comprehensive health data ecosystems capable of supporting preventive care initiatives.

The partnership’s scope includes the development of AI healthcare solutions designed to deliver actionable insights for preventive medical interventions. Through the deployment of IoT-enabled monitoring systems and intelligent data processing frameworks, the organizations seek to establish next-generation platforms that can identify health risks before they escalate into serious conditions. This approach represents a meaningful shift toward proactive rather than reactive healthcare delivery models.

The MOU establishes a foundation for collaborative research, product development, and market implementation of these technologies. Both entities recognize the growing demand for intelligent healthcare infrastructure capable of processing vast quantities of health information in real-time. By pooling technical expertise in artificial intelligence, IoT engineering, and health data analytics, the partnership positions itself to deliver solutions with practical applications across multiple healthcare settings and patient demographics.

The initiative reflects broader industry trends toward digitalization and intelligent health management systems. The integration of AI-powered healthcare solutions with IoT infrastructure creates opportunities for continuous patient monitoring, early warning systems, and personalized preventive care recommendations. Through this strategic collaboration, Kaopiz Holdings and QuantumTX aim to contribute meaningfully to the advancement of preventive healthcare technology and improved health outcomes globally.

The Chairperson of Egypt’s Unified Procurement Authority, Hisham Stait, hosted Libya’s Minister of Health Mohamed Al-Fouj alongside a delegation that included Mohamed Al-Atouq (Advisor to the Minister for Pharmaceutical Affairs), Adel Al-Tajouri (Director of Planning), Sondos Azzam (Director of International Cooperation), Adnan Issa (Director of the Minister’s Office), and Hannibal Khamaj. Both delegations underscored the historical significance of Egypt-Libya healthcare cooperation and reaffirmed their determination to deepen partnership across multiple healthcare dimensions as part of broader regional integration and development objectives.

Stait provided an overview of Egypt’s Unified Procurement Authority, contextualizing its importance within the country’s comprehensive healthcare reform strategy. The authority functions as one of five foundational institutions designed to modernize Egypt’s healthcare infrastructure and operates as the centralized body responsible for acquiring pharmaceuticals, medical supplies, and medical equipment. This centralized approach ensures adherence to quality benchmarks while simultaneously achieving financial efficiency across the healthcare system.

The authority has catalyzed notable expans ion within Egypt’s pharmaceutical manufacturing base. The number of pharmaceutical production facilities has grown substantially, increasing from roughly 150 to approximately 180 factories in recent years. Alongside this manufacturing growth, significant achievements have been realized in domestically producing medical supplies and equipment, reducing dependence on imported products.

To encourage companies to participate in Egypt-Libya healthcare cooperation through localization programs, the authority provides structured incentive mechanisms. These include off-take agreements and assured market participation guarantees, designed to attract investment and strengthen domestic manufacturing capabilities across the medical sector.

Stait detailed Egypt’s network of strategic medical warehouses, constructed in accordance with international operational standards. These facilities maintain secure reserves of medicines, medical supplies, and medical equipment. The warehouses employ sophisticated technological infrastructure and intelligent management systems to guarantee pharmaceutical and medical security while ensuring product availability and integrity.

The Libyan delegation demonstrated considerable enthusiasm for Egypt’s strategic warehouse approach, identifying it as an exemplary model of contemporary medical supply chain management. Ministers and advisors expressed their intention to leverage Egyptian technical expertise and operational knowledge to enhance Libya’s own medical supply infrastructure.

Al-Fouj recognized Egypt’s instrumental role in advancing healthcare delivery standards throughout the region and conveyed Libya’s commitment to benefiting from Egyptian knowledge, particularly regarding medical industry localization, professional development initiatives, and sourcing Egyptian pharmaceuticals and medical supplies.

Egyptian pharmaceutical and medical products are recognized for meeting rigorous quality requirements and maintaining internationally accredited certifications. This positioning strengthens their potential contribution to Libya’s healthcare modernization efforts and the enhancement of medical services delivered to Libyan populations. Al-Fouj indicated that accessing such high-standard products would substantially support healthcare advancement for Libyan citizens.

Both parties concluded their discussions with a commitment to sustained coordination on advancing healthcare collaboration initiatives. Ongoing dialogue will focus on pharmaceutical distribution channels, medical industry localization opportunities, and healthcare service development. These collaborative efforts are directed toward achieving reciprocal benefits for both Egypt and Libya as they work toward strengthened healthcare systems and improved medical outcomes.

Commenting on the milestone, Medtronic ENT business president Sean Haag said: “Receiving the CE mark for the Stealth AXiS surgical system in ENT procedures is an important milestone for ENT surgeons and patients across Europe. “This platform builds on our long legacy in surgical navigation while introducing a more connected, intelligent system specifically designed for the future of ENT surgery.” The Stealth AXiS ENT Platform supports a range of procedures, including minimally invasive sinus surgery, skull base interventions and sinus balloon treatments. It is also integrated with Medtronic’s AiBLE ENT smart ecosystem, which links technologies and helps optimise workflow across ENT surgical settings.

Medtronic ENT business international vice-president Panos Drakoulas said: “We’re excited to reach this milestone and expand access to the Stealth AXi surgical system across Europe. “ENT surgeons are looking for technology that fits naturally into their workflow while helping them navigate basic to highly complex anatomy with confidence. “The Stealth AXiS surgical system was built with those insights in mind, and we look forward to supporting more surgeons and patients across the region.” The European approval follows US Food and Drug Administration (FDA) clearance for ENT applications earlier this year. The system has also received CE marking for spinal and cranial procedures. In May 2026, Medtronic also secured CE mark approval for its VitalFlow Transport Frame Air and Ground accessory, which is used with the VitalFlow extracorporeal membrane oxygenation system.

Riverpoint Medical develops and manufactures minimally invasive surgical consumables and implantable technologies used in sports medicine, trauma, and cardiovascular surgery. Its portfolio includes advanced surgical fibers, implantable materials, suture anchors, surgical instruments, and proprietary coating technologies supplied to major medical OEMs under private-label arrangements. Commenting on the acquisition, Matthijs Glastra, chair and chief executive officer of Novanta, said, “Riverpoint Medical is an exceptional business, a market leader in high-growth minimally invasive surgical consumables that is perfectly aligned with our strategic direction and our business model.” He added, “Riverpoint Medical is growing revenue and cash flows at twice the rate of Novanta, with an expected long-term annual revenue growth outlook of 12% to 15%.” According to Novanta, the acquisition is expected to double recurring medical consumables revenue to approximately $300 million and raise medical end-market exposure to about 60% of total revenue. The company also estimates that the deal will expand its addressable market opportunity by roughly $2 billion while adding manufacturing capacity closer to customers.

Founded in 1964 and headquartered in Portland, Oregon, Riverpoint operates manufacturing facilities in Portland and San Jose, Costa Rica. The company has established expertise in biomedical textiles, advanced material science, and regulatory support, including management of the FDA 510(k) clearance process for OEM customers. Doug King, chief executive officer of Riverpoint Medical, said, “Novanta is the ideal partner for Riverpoint Medical and for the customers we serve.” He added, “We have built a uniquely capable business that serves as the innovation engine behind some of the most important new product development programs of our OEM customers in sports medicine, trauma and cardiovascular surgery.” King said the combination will broaden customer access to surgical solutions while supporting manufacturing expansion, product development, and entry into new markets.

For Arlington Capital Partners, the sale concludes a period of growth focused on expanding Riverpoint’s manufacturing footprint, product offerings, and market reach. “When we first partnered with Riverpoint, we recognized a company with exceptional engineering talent and differentiated capabilities in surgical fiber and biomedical textiles,” said Matt Altman, managing partner at Arlington Capital Partners. “Together with the management team, we’ve meaningfully expanded its product portfolio, scaled its manufacturing, and broadened its end markets.” Novanta expects Riverpoint to generate approximately $80 million in adjusted EBITDA, including synergies, during 2027 and has identified more than $80 million in cumulative profit and cash flow synergies over five years. Once completed, Riverpoint Medical will join Novanta’s Medical Solutions operating segment. The transaction will be financed through cash on hand, borrowings under the company’s existing credit facility, and proceeds from a recently completed $300 million equity offering.

The Jaide Health platform provides AI-assisted language support for routine verbal exchanges and written translations commonly used throughout the healthcare process. These include intake-related communications, discharge information, and other administrative interactions where language barriers can create delays for patients and healthcare staff. According to AMN, human interpreters will continue to be used when conversations require greater clinical accuracy, empathy, and patient-safety considerations. The acquisition is intended to address communication gaps that often arise outside physician consultations and acute-care settings.

“This is an important strategic move in AMN’s ongoing mission to improve access to care for all,” said Cary Grace, President and CEO of AMN Healthcare. “By expanding language support across more moments in the healthcare journey, we can help health systems deliver a more seamless experience for patients and care teams while continuing to rely on the critical expertise of our qualified interpreters when it matters most.”

The Jaide Health solution is already in use with clients operating across multiple healthcare environments, where it has been applied to patient communications and workflow support. AMN stated that the technology has demonstrated value in real-world healthcare settings and will now become part of its broader language services offering. As part of the transaction, the Jaide Health team will join AMN Healthcare.

“We believe we’ve built one of the strongest solutions in the market, and joining AMN Language Services lets us reach more patients through AMN’s scale and clinical-quality standards,” said Joe Corkery, MD, CEO and co-founder of Jaide Health. “AMN was our first choice because of our shared commitment to quality. Together, we can pair smart AI assistance with the high standards of AMN’s human interpreting to provide LEP patients with a voice outside of clinical encounters, which we know leads to better outcomes and experiences.”

Financial terms of the deal were not disclosed. The AMN Healthcare Acquires Jaide Health transaction expands language support capabilities across the patient journey, while the AMN Healthcare Acquires Jaide Health announcement also reinforces the continued importance of human interpreters in healthcare communications.

The decision follows findings that equated the daily time savings to roughly five weeks per staff member each year. Health Innovation and Safety Minister Preet Kaur Gill said: “Every day, doctors, nurses and other healthcare professionals spend valuable time on administrative tasks that take them away from patients.” She added: “By rolling out Microsoft Copilot across the NHS, we can reduce that burden, free up clinicians’ time and help staff focus on what they do best, caring for patients.” Rob Thompson, Chief Digital, Data and Technology Officer at NHS England, said: “The potential to save clinical staff nearly a day’s worth of admin time every fortnight could be a gamechanger for patients.” He added: “We’re making sure every pound is spent on cutting waiting times and boosting care through the Plan for Change and 10 Year Health Plan.”

The deployment will support a range of operational and administrative functions across NHS England. Ward clerks will use the technology for patient discharge processes, rota planning and bed management, while medical secretaries will apply it to meeting documentation and template creation. Administrative teams in HR, finance and procurement will also use the platform, and management groups will employ it to prepare board papers and briefings. NHS England will additionally gain access to Copilot Studio, enabling individual NHS Trusts to build customized AI agents for workflow automation, including support for helpdesk operations, complaints handling, freedom of information requests and financial processing. Agent 365 will provide governance controls to ensure those agents comply with organizational security requirements.

Microsoft UK and Ireland CEO Darren Hardman said: “By rolling out Microsoft 365 Copilot at scale, NHS teams can cut through everyday admin and spend more time where it matters most.” He added: “Bringing AI safely into the flow of healthcare will help ease pressures, improve productivity, and support better decision-making across the health service.” NHS England serves approximately 56 million people and employs around 1.4 million staff, making this one of the largest enterprise AI deployments undertaken by a healthcare organization. The structured onboarding programme will run for 12 months and is intended to support adoption across the health system while providing a large-scale example of AI implementation in public healthcare.